• Fri, September 9, 2022
Michael Ulz Maintained (YMAB) at Hold with Increased Target to $17 on, Sep 9th, 2022
Michael Ulz of Morgan Stanley, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Hold with Increased Target from $15 to $17 on, Sep 9th, 2022.
Michael has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $27 on, Friday, June 24th, 2022
Like: 👍
